Across TCGA pan-cancer cohorts, SMIM7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMIM7 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher SMIM7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMIM7 expression acts as an unfavorable survival marker.

LAML, UCEC, and LIHC are the cancer types where SMIM7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.140	0.572	.040	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.020	0.414	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SMIM7 tumor-vs-normal RNA expression · all SMIM7 data types